Exploring Innovative Leishmaniasis Treatment: Drug Targets from Pre-Clinical to Clinical Findings |
| |
| Authors: | Wanessa Santana Simone S C de Oliveira Mariana H Ramos André L S Santos Silvio S Dolabella Eliana B Souto Patrícia Severino Sona Jain |
| |
| Institution: | 1. Post-Graduation Program in Industrial Biotechnology, University of Tiradentes, Aracaju, Sergipe, Brazil;2. Institute of Microbiology Paulo de Góes, Department of General Microbiology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil;3. Laboratory of Entomology and Tropical Parasitology, Department of Morphology, Federal University of Sergipe, São Cristóvão, Sergipe, Brazil;4. Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, Coimbra, Portugal |
| |
| Abstract: | Leishmaniasis is a group of tropical diseases caused by parasitic protozoa belonging to the genus Leishmania. The disease is categorized in cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and visceral leishmaniasis (VL). The conventional treatment is complex and can present high toxicity and therapeutic failures. Thus, there is a continuing need to develop new treatments. In this review, we focus on the novel molecules described in the literature with potential leishmanicidal activity, categorizing them in pre-clinical (in vitro, in vivo), drug repurposing and clinical research. |
| |
| Keywords: | leishmaniasis new targets pre-clinical clinical drug repurposing |
|
|
